USA MOBILE DRUG TESTING, by the numbers
Every figure below comes from real financed deals — what buyers paid, where, and how the loans performed.
SBA Franchise Directory: listed ✓ (identifier S1839)
1 deals since 2020 · typical deal $284K
1
Deals since 2020
$284K
Typical deal
1
Deals since FY2025
—
Too few deals to score risk
What buyers pay for USA MOBILE DRUG TESTING
Most USA MOBILE DRUG TESTING deals financed between $284K and $284K. Above $284K, you're paying more than 75% of buyers did — make the seller earn it.
- Monthly payment (10-yr)
- $3,952
- Down payment (10%)
- $32K
- Cash to close (all-in)
- $42K
Estimates at today's rates and standard 7(a) terms. Not a loan offer.
Could you get the loan?
Three answers. No documents, no credit pull.
Credit score
Available cash (you'll need ~$42K)
Experience
Recent financings
- Jonathan J. Voccia in Warwick, RI — $284K (2025) · purchase · Citizens Bank, National Association
- Program
- Preferred Lenders Program
- Rate at approval
- 11% fixed
- Term
- 120 mo (10 yrs)
- SBA guaranteed
- $213K (75%)
- Approval → funding
- 94 days
- Approved
- 5/5/2025
- First disbursed
- 8/7/2025
- Loan status
- Current
- Loan type
- Term loan
- Collateral
- Required
- Business type
- Corporation
- Jobs supported
- 1
- Business age
- Change of Ownership
- Industry
- Medical Laboratories
If you were the buyer here
- Est. deal size
- $316K
- Est. down payment (10%)
- $32K
- Est. cash at closing
- $42K
- Monthly payment
- $3,912
- Annual debt service
- $47K
- Cash flow needed (1.25×)
- $59K
Estimates only — not guaranteed accurate. The loan amount, rate,and term come from the public record; the rest assumes the standard 10% buyer injection plus typical guaranty and closing costs. The actual deal's terms and costs likely differed.
Funded by Citizens Bank, National Association · Lender record →
Your business? Claim this record · Request removal
Hover or tap a deal for terms: program, rate, SBA guarantee, days to fund.
One of these businesses yours? Claim your listing or request removal.
Free · No documents · Usually same-day
Serious about buying a USA MOBILE DRUG TESTING?
Get qualified with a franchise lending specialist before discovery day — know your number first.
Who funds USA MOBILE DRUG TESTING — and where
Every dot is a financed USA MOBILE DRUG TESTING — 1 mapped.
Financed USA MOBILE DRUG TESTING locations — list all 1 as text
- Jonathan J. Voccia — Warwick · $284K · FY2025 · Medical Laboratories
Top lenders for this brand
Most active states
- 1.Rhode Island (1 loans)
Represent USA MOBILE DRUG TESTING?
Claim this brand page free to keep the numbers in context, add your story, and hear about qualified buyers early.
Common questions
How much does a USA MOBILE DRUG TESTING cost to buy or open?
The typical deal for USA MOBILE DRUG TESTING is $284K across 1 transactions since 2020. With the SBA's 10% minimum down payment, that points to roughly $31K of buyer cash on a typical deal.
How risky is USA MOBILE DRUG TESTING?
USA MOBILE DRUG TESTING has 1 SBA loan on record since 2020 — too few to score a reliable failure rate. Judge the unit economics and the franchisor's disclosure document, not a small sample.
Can I finance a USA MOBILE DRUG TESTING with an SBA loan?
Yes — USA MOBILE DRUG TESTING has been SBA-financed 1 times since FY2025, which means it clears the SBA Franchise Directory requirement regularly. Confirm current listing before signing an LOI.
Buying a USA MOBILE DRUG TESTING franchise
Most USA MOBILE DRUG TESTING buyers finance the purchase or build-out with an SBA 7(a) loan — up to 90% of the cost with roughly 10% down. The typical USA MOBILE DRUG TESTING deal financed for $284K, which points to about $31K of buyer cash on a typical purchase. USA MOBILE DRUG TESTING is listed in the SBA Franchise Directory (identifier S1839), so it's eligible to finance today — confirm current listing with your lender before the LOI. See the lenders that already fund USA MOBILE DRUG TESTING — a bank that knows the brand approves faster — or pre-qualify for financing to see your likely loan size first.
AI summary
This profile summarizes public SBA financing activity for USA MOBILE DRUG TESTING — lender activity, typical loan sizes, financing history, and risk and failure signals where available — via CapBench SBA Intelligence. CapBench is not a lender.
Source: CapBench SBA Intelligence, based on public SBA, lender, franchise, FDIC, and related records. CapBench is not a lender and does not guarantee financing.
Agent summary
This page summarizes public SBA 7(a) financing for USA MOBILE DRUG TESTING — typical deal size, the lenders that fund the brand, geography, and failure-rate context — from CapBench SBA Intelligence. USA MOBILE DRUG TESTING is confirmed in the SBA Franchise Directory here; CapBench is not a lender and does not sell franchises.
- 1 SBA 7(a) deal since 2020
- $284K typical deal
- 1 deals since FY2025
- Too few deals to score a reliable failure rate
- SBA Franchise Directory: listed (identifier S1839)
- Top lenders: Citizens Bank, National Association
- Data freshness:
- SBA records through 2026-05-31; FDIC through 2026-03-31; page updated 2026-06-17.
- Sources:
- Public SBA 7(a) loan records; FDIC institution data (BankFind); CapBench lender and franchise enrichment.
- Methodology:
- Sources & methodology
- Informational only — CapBench does not confirm this entity is for sale, eligible for SBA financing, or approved by any lender.
- Figures come from public records and CapBench methodology; verify before relying on them.
- Financing figures are historical SBA loan records, not a current offer or franchise availability. Confirm SBA Franchise Directory listing with your lender before an LOI.
Still have questions about buying a USA MOBILE DRUG TESTING?
Five minutes with a specialist who's seen USA MOBILE DRUG TESTING deals close answers more than an hour of searching. Free, usually same-day.
Represent USA MOBILE DRUG TESTING?
Claim this brand page to keep the numbers in context, add your story, and hear about qualified buyers early.
CapBench analysis of public lending records, FY2020–present. Charge-off rate measured on the FY2020–23 cohort. Not affiliated with USA MOBILE DRUG TESTING.